Michael Aaron Morse, MD

Professor of Medicine
Professor in the Department of Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address morse004@mc.duke.edu

We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1993 - 1996
  • Medical Resident, Medicine, University of Washington, 1990 - 1993
  • M.D., Yale University, 1990

Grants

Publications

Jia, Jingquan, Michael A. Morse, Rebecca J. Nagy, Richard B. Lanman, and John H. Strickler. “Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer.” Front Oncol 8 (2018): 305. https://doi.org/10.3389/fonc.2018.00305.

PMID
30211110
Full Text

Curti, Brendan, Gregory A. Daniels, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Theodore F. Logan, Jatinder Singh, et al. “Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.” J Immunother Cancer 5, no. 1 (December 19, 2017): 102. https://doi.org/10.1186/s40425-017-0307-5.

PMID
29254506
Full Text

Osada, Takuya, Kensuke Kaneko, William R. Gwin, Michael A. Morse, Amy Hobeika, Brian W. Pogue, Zachary C. Hartman, Philip F. Hughes, Timothy Haystead, and H Kim Lyerly. “In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7531–42. https://doi.org/10.1158/1078-0432.CCR-17-1453.

PMID
28993342
Full Text

Kopetz, Scott, Vittorina Zagonel, Michael J. Overman, Ray McDermott, Michael A. Morse, Franklin L. Chen, James Lee, et al. “Microbiome analyses in patients with previously treated, deficient DNA mismatch repair/microsatellite instability-high metastatic colorectal cancer treated with nivolumab +/- ipilimumab: CheckMate 142.” In Journal for Immunotherapy of Cancer, Vol. 5. BMC, 2017.

Scholars@Duke

Le, Dung T., Vanessa M. Hubbard-Lucey, Michael A. Morse, Christopher R. Heery, Andrea Dwyer, Thomas H. Marsilje, Arthur N. Brodsky, et al. “A Blueprint to Advance Colorectal Cancer Immunotherapies.” Cancer Immunol Res 5, no. 11 (November 2017): 942–49. https://doi.org/10.1158/2326-6066.CIR-17-0375.

PMID
29038296
Full Text

Lonardi, S., T. Andre, K. Y. M. Wong, M. Morse, R. McDermott, A. Hill, A. Hendlisz, et al. “Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study.” In Ann Oncol, 28 Suppl 6:vi3, 2017. https://doi.org/10.1093/annonc/mdx422.001.

PMID
31962658
Full Text

Jiang, Ni, Guoliang Qiao, Xiaoli Wang, Michael A. Morse, William R. Gwin, Lei Zhou, Yuguang Song, et al. “Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.” Clin Cancer Res 23, no. 17 (September 1, 2017): 5066–73. https://doi.org/10.1158/1078-0432.CCR-17-0492.

PMID
28611200
Full Text

Overman, Michael J., Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A. Morse, Jayesh Desai, et al. “Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.” Lancet Oncol 18, no. 9 (September 2017): 1182–91. https://doi.org/10.1016/S1470-2045(17)30422-9.

PMID
28734759
Full Text

Kaneko, Kensuke, Takuya Osada, Timothy A. Haystead, Michael A. Morse, and Herbert K. Lyerly. “Abstract 4709: Induction of enhanced tumor-specific immunity by Hsp90 targeted photodynamic therapy (Hsp90-PDT) combined with immune checkpoint inhibition.” In Immunology. American Association for Cancer Research, 2017. https://doi.org/10.1158/1538-7445.am2017-4709.

Full Text

Riedel, Richard F., Kellen L. Meadows, Paula H. Lee, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, Daniel J. George, et al. “Phase I study of pazopanib plus TH-302 in advanced solid tumors.” Cancer Chemother Pharmacol 79, no. 3 (March 2017): 611–19. https://doi.org/10.1007/s00280-017-3256-2.

PMID
28238078
Full Text

Pages